211 related articles for article (PubMed ID: 31217025)
1. Pharmacovigilance strategy: opportunities for cross-national learning.
Fermont I
Isr J Health Policy Res; 2019 Jun; 8(1):54. PubMed ID: 31217025
[TBL] [Abstract][Full Text] [Related]
2. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance: An Overview.
Beninger P
Clin Ther; 2018 Dec; 40(12):1991-2004. PubMed ID: 30126707
[TBL] [Abstract][Full Text] [Related]
4. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
Tsintis P; La Mache E
Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
[TBL] [Abstract][Full Text] [Related]
5. Artificial Intelligence and the Future of the Drug Safety Professional.
Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in Crisis: Drug Safety at a Crossroads.
Price J
Clin Ther; 2018 May; 40(5):790-797. PubMed ID: 29605513
[TBL] [Abstract][Full Text] [Related]
7. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.
Trifirò G; Sultana J; Bate A
Drug Saf; 2018 Feb; 41(2):143-149. PubMed ID: 28840504
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance and the digital world in Italy: presentation of the results of a national survey.
Stagi L; Bocchi I; Bianco S; Sirizzotti G; Bernardini D; Calderazzo V; Pirisino G; Grisoni I; Romano S
Ther Adv Drug Saf; 2021; 12():2042098620985991. PubMed ID: 33623659
[TBL] [Abstract][Full Text] [Related]
9. Advancing Drug Safety Through Prospective Pharmacovigilance.
Pitts PJ; Le Louet H
Ther Innov Regul Sci; 2018 Jul; 52(4):400-402. PubMed ID: 29714580
[TBL] [Abstract][Full Text] [Related]
10. European pharmacovigilance: increasingly outsourced to drug companies.
Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
12. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations.
Peters T; Soanes N; Abbas M; Ahmad J; Delumeau JC; Herrero-Martinez E; Paramananda M; Piper J; Smail-Aoudia F; van der Spuij W; Veizovic T; Winstanley G;
Drug Saf; 2021 Jan; 44(1):17-28. PubMed ID: 33289904
[TBL] [Abstract][Full Text] [Related]
13. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
Newell S; Jordan Z
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
[TBL] [Abstract][Full Text] [Related]
14. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
15. Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
Edwards B
Drug Saf; 2004; 27(8):609-17. PubMed ID: 15154832
[TBL] [Abstract][Full Text] [Related]
16. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
[TBL] [Abstract][Full Text] [Related]
17. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.
Salas M; Petracek J; Yalamanchili P; Aimer O; Kasthuril D; Dhingra S; Junaid T; Bostic T
Pharmaceut Med; 2022 Oct; 36(5):295-306. PubMed ID: 35904529
[TBL] [Abstract][Full Text] [Related]
18. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
19. An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting.
Crisafulli S; Khan Z; Karatas Y; Tuccori M; Trifirò G
Expert Opin Drug Saf; 2023; 22(5):373-380. PubMed ID: 37243676
[TBL] [Abstract][Full Text] [Related]
20. Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying Deep-learning Approaches to Individual Case Safety Report Processing.
Abatemarco D; Perera S; Bao SH; Desai S; Assuncao B; Tetarenko N; Danysz K; Mockute R; Widdowson M; Fornarotto N; Beauchamp S; Cicirello S; Mingle E
Pharmaceut Med; 2018; 32(6):391-401. PubMed ID: 30546259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
